Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of DC01 H5N1 influenza vaccine formulations
ACTRN12626000417381Phase 2Active, not recruiting
- Sponsor
- PPD
- Start
- Nov 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of DC01, CpG 1018, aluminium hydroxide and A/H5N1 HA antigen in influenza (5 arms), sponsored by PPD. Primary endpoint: Humoral immunogenicity 21 days after final study injection. Started Nov 2025; status: active, not recruiting.
02
Drugs
DC01CpG 1018aluminium hydroxideA/H5N1 HA antigen
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12626000417381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000417381.